All In Biotech

Drug Trial Radar · NCT06825416

A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

A Multicenter, Randomized, Double-blind, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Arthroplasty

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,165

Actual

Start

Mar 16, 2025

Primary completion

Feb 15, 2026

Study completion Apr 23, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.

Conditions

  • Prevention of Arterial and Venous Thrombosis

Interventions

  • SHR-2004 injectionDrug

    SHR-2004 injection in low dose.

  • SHR-2004 injectionDrug

    SHR-2004 injection in high dose.

  • Enoxaparin sodium injectionDrug

    Enoxaparin sodium injection.

  • Enoxaparin sodium injection placeboDrug

    Enoxaparin sodium injection placebo.

  • SHR-2004 placeboDrug

    SHR-2004 placebo in low dose.

  • SHR-2004 placeboDrug

    SHR-2004 placebo in high dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of asymptomatic deep vein thrombosis (DVT)Time frame: Day 12.
  2. Incidence of non-fatal pulmonary embolism (PE)Time frame: Day 12.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fourth Medical Center of Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.